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Abstract
Objectives: To describe the development, validation and inter-rater reliability of an instrument to measure the quality of
patient decision support technologies (decision aids).
Design: Scale development study, involving construct, item and scale development, validation and reliability testing.
Setting: There has been increasing use of decision support technologies – adjuncts to the discussions clinicians have with
patients about difficult decisions. A global interest in developing these interventions exists among both for-profit and not-
for-profit organisations. It is therefore essential to have internationally accepted standards to assess the quality of their
development, process, content, potential bias and method of field testing and evaluation.
Methods: Scale development study, involving construct, item and scale development, validation and reliability testing.
Participants: Twenty-five researcher-members of the International Patient Decision Aid Standards Collaboration worked
together to develop the instrument (IPDASi). In the fourth Stage (reliability study), eight raters assessed thirty randomly
selected decision support technologies.
Results: IPDASi measures quality in 10 dimensions, using 47 items, and provides an overall quality score (scaled from 0 to 100)
for each intervention. Overall IPDASi scores ranged from 33 to 82 across the decision support technologies sampled (n= 30),
enabling discrimination. The inter-rater intraclass correlation for the overall quality score was 0.80. Correlations of dimension
scores with the overall score were all positive (0.31 to 0.68). Cronbach’s alpha values for the 8 raters ranged from 0.72 to 0.93.
Cronbach’s alphas based on the dimension means ranged from 0.50 to 0.81, indicating that the dimensions, although well
correlated, measure different aspects of decision support technology quality. A short version (19 items) was also developed
that had very similar mean scores to IPDASi and high correlation between short score and overall score 0.87 (CI 0.79 to 0.92).
Conclusions: This work demonstrates that IPDASi has the ability to assess the quality of decision support technologies. The
existing IPDASi provides an assessment of the quality of a DST’s components andwill be used as a tool to provide formative advice
to DSTs developers and summative assessments for those who want to compare their tools against an existing benchmark.
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Introduction
There has been increasing interest in the use of ‘decision aids’
[1], defined as adjuncts to the discussions clinicians have with
patients during deliberations about decisions: these aids provide
information about options and help clarify personal values [2].
These adjuncts range from leaflets through face to face methods
such as coaching or counselling to interactive multimedia
websites. To describe this generic family of clinician-patient
interventions we will use the term decision support technologies
(DSTs) [3], corresponding with the internationally recognised
need to assess the impact of ‘health technologies’ [4]. DSTs are
complex interventions which require detailed assessment to
ensure safe use in healthcare contexts [3] because they help
make options explicit, provide information about harms and
benefits, clarify patient values’ and provide structured means to
help people deliberate when making decisions. Although there
are published methods to assess the quality of clinical practice
guidelines [5], DSTs go further and address issues of equipoise
for which patients need to deliberate about difficult choices [6].
However, as yet, there are no reliable methods to assure the
quality of DSTs development process, content, potential bias,
and method of field testing and evaluation – a gap which we
address in this study. We did not intend to develop methods to
assess how DSTs are used in practice, in the clinical encounter,
although we recognise that this is an important area that requires
further work.
There are reports that DSTs have achieved a ‘tipping point’ in
the US and are widely accessed by increasing numbers of patients
[1]. The ability of DSTs to improve the quality of decisions and
enable reductions in discretionary surgery and invasive procedures
without adverse effects on health outcomes has been demonstrated
in clinical trials [2,7]. The central role that these technologies will
play in future healthcare systems is increasingly recognised [1,8–
10]. Over the last decade, the interest in developing DSTs has
moved beyond research groups and has entered the commercial
world. A global interest in developing DSTs has emerged among
both for-profit and not-for-profit organisations. It is therefore
essential to have a set of internationally accepted standards to
assess their quality, to assess whether interests are declared and
whether they are unduly biased [8,9].
The International Patient Decision Aid Standards (IPDAS)
Collaboration produced a checklist for the assessment of DSTs
[11]. The checklist was rigorously developed in a two stage web-
based Delphi process using online rating process to enable
international collaboration. A total of 122 individuals from four
stakeholder groups (researchers, practitioners, patients, policy
makers) representing 14 countries reviewed background evidence
summaries, and rated the importance of 80 criteria in 12 quality
dimensions. Second round participants received feedback from the
first round and repeated their assessment of the 80 criteria plus
three new ones. The IPDAS checklist enabled broad assessments
in 12 dimensions: systematic development process, providing
information about options; presentation of probabilities; clarifica-
tion of values; use of patient stories; information about guiding or
coaching; disclosure of interests; providing internet access;
balanced presentation of options; use of plain language; use of
up-to-date evidence; and effectiveness. The IPDAS checklist allows
users, developers and others to assess whether these technologies
contain the suggested components and judge whether they
underwent rigorous development and evaluation. It has been
used in updating the Cochrane systematic review of DSTs and to
guide the development of DSTs [12,13].
However, the checklist was not designed to provide precise,
quantitative assessments, such that judgements could be made
about the quality of DSTs, either at item, dimension or global
levels. In addition, because not all checklist items were applicable
to every DST, comparability, even at the checklist level, was not
possible. Given interest in being able to assess these DSTs at a
more precise level of detail — in terms of how they were developed
and field tested, whether their content was valid and whether
effectiveness had been evaluated with patients facing relevant
decisions — the IPDAS Collaboration agreed that achieving this
objective would require an instrument capable of quantitatively
assessing the quality of DSTs. The aim of this article is to describe
the development, validation and inter-rater reliability of an IPDAS
instrument (IPDASi), built on the existing framework.
Methods
IPDASi was developed in four stages.
Stage 1 Refinement and preparation of instrument
(IPDASi v1)
The published IPDAS checklist required transformation into a
quantitative instrument, although we agreed to adopt the
dimension-item framework. As part of this preparation, a group
of researchers (GE, DS, RT, CB, SB, TW) used the existing
checklist and dimension-item framework to score three purpose-
fully selected DSTs, representing different design approaches and
where our prior overall assessments indicated variable quality.
These were Healthwise’s Breast Cancer Surgery (BCS), web-based
information, Bastian&McBrides Hormone Replacement Therapy
(HRT), an illustrated booklet, and Wolf et al’s Prostate Specific
Antigen (PSA) screening, a brief text-based script. A binary (yes/
no) and ‘not applicable’ scale was proposed; comments were
collected on item applicability. Tabulations and qualitative
analyses were performed but inter-rater correlations were not
calculated.
Stage 2 IPDASi Confirmation of items (IPDASi v2)
On the basis of the results of Stage 1, a refined version IPDAS
instrument (IPDASi v2) was designed and used in Stage 2. The
non-applicable option was removed, and in this and all subsequent
versions, a 4-point rating scale was used for each item, with
possible responses as follows: strongly agree = score 4 (the issue is
addressed clearly and comprehensively); agree = score 3 (the issue
is addressed but with room for improvement); disagree = score 2
(the DST fails to clearly address the issue); strongly disagree = -
score 1 (the DST totally fails to address the issue). In common with
the binary (yes/no) scale it replaced, the scale intentionally does
not include a midpoint expressing neutrality. Items in the ‘balance’
dimension were integrated into the ‘information’ dimension. The
web dimension was not applicable to all DSTs, therefore removed.
A website was created for data collection (http://www.ipdasi.org/
). Scale anchor point descriptions were developed for all items.
Five raters, two in the UK (MA-D and SS, Cardiff) and three in
North America (ED and SK in Ottawa and MP in Providence)
were familiarised with IPDASi v2, prior to using it to score the
three previously selected DSTs, and asked to comment on item
phrasing. Members of the IPDASi development group were asked
to view the IPDASi instrument online and comment on item
phrasing. For IPDASi v2 and subsequent versions, item scores
were rescaled to be 0 to 100. At Stage 2, only an unweighted
average of all items was calculated, as our focus was not on
dimension scores. Analysis included inter-rater reliability using
Assessing Decision Support
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intraclass correlations for two way random effects at item and
global score levels [14].
Stage 3 IPDASi Validation Study
Based on the results of Stage 2, a third version, IPDASi v3 was
designed. This retained the majority of items from Stage 2, albeit
with changes to phrasing. It comprised 47 items representing 10
dimensions. 9 dimensions applicable to all DSTs relate to
Information (8 items); Probabilities (8 items); Values (4 items);
Decision Guidance (2 items); Development (6 items); Evidence (5
items); Disclosure (2 items); Plain language (1 item); Evaluation (2
items). One additional dimension (9 items) relates to decisions
based around tests or screening. Feedback from the comments
resulted in more detailed anchor scale descriptions and standard-
ization of descriptions.
IPDASi v3 was then used in a validation study to assess the
quality of a sample of DSTs. Two approaches were used to
achieve a sample of DSTs. First, five major producers of publically
available DSTs were identified (The Foundation for Informed
Medical Decision Making, Healthwise, Mayo Clinic, Midwives
Information and Resource Service (MIDIRS) and Ottawa Health
Decision Centre (OHDeC). Three DSTs from each producer were
chosen at random, giving a total of 15. Second, 66 English-
language DSTs, for which contact details were available, were
chosen at random from the Cochrane inventory maintained by the
University of Ottawa (http://decisionaid.ohri.ca/cochinvent.php),
and their developers were approached and asked:
1) Whether the DST was in current use and free of charge to
clients;
2) For consent to assess the DST using IPDASi; and
3) For copies or information about documentation (published
reports or peer reviewed articles) about the development or
evaluation of the DST.
Each DST included in the sample was prepared for assessment
in a standardised way. Background documents (relevant publica-
tions, reports) and all DST content were made available online
(either in pdf or html formats; videos were converted into
Windows Media Video format) for raters to assess. Table 1
provides details of the DSTs that were included in the sample, and
the results of the IPDASi assessments.
Eight raters with diverse backgrounds and training were trained
to undertake independent ratings: four in the UK (MA-D, MS, NJ,
SS in Cardiff) and four in North America (SK, ED, AS in Ottawa;
MP in Providence). Each DST was scored by two raters, one
chosen randomly from each location, such that one rating was
done in UK and the other in North America. New raters were
asked to pilot the instrument on a ‘test’ DST and new raters also
had access to raters who had completed the Stage 2 assessment if
they required advice on item interpretation.
As in Stage 2, each item was scored on a 4-point scale, rescaled
from 0 to 100, and dimension means were calculated. Two overall
scores were calculated, scaled 0 to 100: the unweighted mean of all
items (38 or 47, depending on whether the DST addressed a
treatment or a test/screening decision) and the weighted mean
score, a mean of the 9 or 10 dimension-specific means. The latter
score upweights items belonging to dimensions comprising few
items and downweights items from dimensions with many, but
each dimension contributes an equal weight into the final score.
Summary statistics were calculated for dimension scores and
unweighted and weighted overall means. Weighted means were
modelled by rater and tool in a two-way balanced incomplete
ANOVA model. Intraclass correlations and Cronbach’s alpha, by
each rater and by dimension means, were also calculated. The
quality of each DST was then characterised by the average of the
weighted mean scores from the two raters, adjusted by the model
to take account of their personal propensity to give higher or lower
scores. We wanted to predict the degree of accuracy if others used
IPDASi in the future, considering one or two raters, known to us
(i.e. one of the existing eight raters) or unknown to us. To achieve
this, components of variation were determined by Bayesian
modelling (Markov chain Monte Carlo) using WinBugs software
[15], to arrive at estimated confidence interval half-widths for
differing future rating situations. The raters’ qualitative comments
were summarised.
Stage 4 Agreement on IPDASi-SF (short form)
A core set of items was also chosen to develop a ‘short form’
(IPDASi-SF) aiming to test whether a ‘minimum’ quality
threshold could be established. By agreement in the development
group, these criteria were chosen based on having an equimedian
score of 9 (i.e. maximum agreement) in the IPDAS consensus
process [11]. The equimedian is designed to represent the
cumulative distribution function for a population with equal
numbers in each of the four stakeholder groups [11]. In addition,
core-set items represented key concepts for each dimension. The
19 items selected for the IPDASi-SF consisted of 3 items for
tests/screening and 16 others for all DSTs including: Informa-
tion (4 items: options available, positive features, negative
features, and fair comparison); Probabilities (3 items: reference
class, event rates, compare probabilities); Values (1 item:
personal importance); Development (3 items: patients’ needs,
impartial review, tested with patients) ; Disclosure (1 item:
information about funding); Evaluation (2 items: knowledge,
improved decision quality); Evidence (2 items: citations to
studies, production date). The three items selected for the test/
screening dimension included: next steps, chances of detection,
non-symptomatic. These SF items were not highlighted for
special attention during the rating process. Unweighted mean
scores were calculated (i.e. all SF items and not the means
related to their respective dimensions), and correlations (Pearson)
with the IPDASi overall mean adjusted weighted score (Table 2).
Results
Table 2 provides a synopsis of the different versions, detailed in
the four stages.
Stage 1 Refinement and preparation of instrument
(IPDAS v1)
Results of the seven raters were compared. The number of
comments made at the interpretation level and the wide variation
in scoring indicated a need for further item development. In
addition some items had double criteria. In October 2006, five
researchers met (AC, AOC, DS, CB&GE) and, using the results of
this Stage, judged each item against two criteria, clarity and
feasibility of measurement. All item phrasings were modified and it
was decided to base the development of IPDASi on the following
assumptions.
1. All items should be applicable to the assessment of all DSTs. This
enables the computation of a standard quality score per DST
with no adjustment for specific content. An exception was
made for DSTs designed to guide deliberations about
undertaking diagnostic or screening tests. This type of DST
would be subject to an additional dimension of items relating
specifically to information on test characteristics.
Assessing Decision Support
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2. All items should meet the criterion of measurement feasibility.
At this Stage, we decided to have 10 dimensions in IPDASi,
mirroring the dimensions agreed in the IPDAS consensus
process. Further information on dimension and items is
presented in Stage 3.
Stage 2 Refinement and preparation of instrument
(IPDAS v2)
Mean scores on a 0–100 scale for the three DSTs were as
follows, with SDs reflecting inter-rater variation: HRT 68.7 (6.9);
BCS 46.0 (6.5); PSA 38.5 (6.4). The intraclass correlation
coefficient was 0.89. These results provided sufficient confidence
to refine the instrument for a larger reliability study (Stage 3).
Qualitative comments revealed where more specific item anchors
descriptors were required, achieved collaboratively using a shared
online spreadsheet. Discussions regarding dimension weighting led
to agreement that the mean of each dimension should contribute
equally to the total score.
Stage 3 Dual rater assessments of 30 DSTs (IPDAS v3)
Table 1 describes the sample of DSTs and provides the results.
Table 3 lists the items used in IPDAS v3. Three DSTs were
assessed from each of the five selected major producers. The
other 15 were obtained by approaching 36 developers (repre-
senting 47 DSTs). Eighteen developers did not respond and we
found that five of the DSTs were no longer in use. After repeated
contacts, 13 developers (representing 15 DSTs) agreed to
participate in the study, resulting in an overall sample of 30
DSTs.
The time taken to assess a DST varies considerably, dependent
on its complexity. A simple DST comprising a leaflet could be
completed in two hours but assessing multimedia web-based DST
required at least 8 hours. A weighted overall score (scaled from 0
to 100) for each DST is shown, averaged over two raters, and then
adjusted for the pair of raters. Adjusted IPDASi scores ranged
widely from 33 to 82 (Table 2). The intraclass correlation for the
weighted overall score was 0.80. Correlations of dimension scores
with the weighted overall score were all positive (0.31 to 0.68).
Cronbach’s alpha values for the 8 raters ranged from 0.72 to 0.93.
Cronbach’s alphas based on the means in the 9 dimensions ranged
from 0.50 to 0.81, indicating that the dimensions, although
relatively well correlated, measure different aspects of DST
quality. Calculations of the standard deviation (SD) presenting
imprecision using a Bayesian model based on the existing eight
raters, and projected for different number of known (one of the
existing eight raters used) and unknown raters, for whom we have
no information about their scoring tendencies, resulted in the
following estimates: two known raters, 6.6; one known rater, 9.4;
two unknown raters, 9.3; one unknown rater, 13.1. Qualitative
comments were received on some items, requesting clarifications.
This was achieved by adding examples and more descriptive
elements to the anchor statements.
Stage 4 Agreement on IPDASi short form
The mean unweighted score for the short-form 16 item IPDASi
was 56.1, similar to 56.3 for all items. The correlation of the
unweighted IPDASi-SF to the overall mean weighted score
(IPDASi score in Table 2) is 0.87 (CI 0.79–0.92). The ranking of
the DSTs according to the SF version are very similar, with
adjusted scores ranging from 34.5 to 83.1. DST number 32 still
ranks highest, but the order shifts at the lower end of the scale.
However, the aim of the IPDASi-SF was not to rank DSTs in
order of quality but to determine whether or not a limited set of
IPDASi items may be useful in determining minimal levels of
quality.
Table 2. Development of IPDASi versions and IPDASi-SF: item retention and dimension merging.
Stage 1 2 3 4
IPDASi version IPDASi v1 IPDASi v2 IPDASi v3 IPDASi SF
Number of items 62* 48 47 19
Assessors/Raters Expert group (GE, DS, RT,
CB, SB, TW).
Cardiff: MA-D, MS, NJ, SS;
North America: SK, ED, AS MP.
Cardiff: MA-D, MS, NJ, SS;
North America: SK, ED, AS MP.
Cardiff: MA-D, MS, NJ, SS;
North America: SK, ED, AS MP.
Number of DSTs evaluated 3 3 30 30
Dimensions
Information 8 8 8 4
Probabilities 10 8 8 3
Values 3 5 4 1
Decision Guidance 3 2 2 –
Development 7 6 6 3
Evidence 6 5 5 2
Disclosure 2 2 2 1
Plain Language 3 1 1 –
Evaluation 7 2 2 2
Test 5 9 9 3
Web-based 6 Items did not meet inclusion assumption of being applicable to all DSTs and were therefore not
included.
Balance 2 This dimension was merged with probabilities.
*IPDASi v1 is equivalent to the IPDAS Checklist.
"Test dimension items applicable to relevant DSTs.
doi:10.1371/journal.pone.0004705.t002
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Table 3. IPDASi v3 Dimensions and Items.
Dimension Item
Information 1. The decision support technology describes the health condition or problem (intervention, procedure or investigation) for which
the index decision is required
Providing information about
options in sufficient detail for
making a specific decision
2. The decision support technology describes the decision that needs to be considered (the index decision)
3. The decision support technology describes the options available for the index decision
4. The decision support technology describes the natural course of the health condition or problem, if no action is taken.
5. The decision support technology describes the positive features (benefits or advantages) of each option
6. The decision aid describes negative features (harms, side effects or disadvantages) of each option.
7. The decision support technology makes it possible to compare the positive and negative features of the available options.
8. The decision support technology shows the negative and positive features of options with equal detail (for example using similar
fonts, order, and display of statistical information).
Probabilities 1. The decision support technology provides information about outcome probabilities associated with the options (i.e. the likely
consequences of decisions)
Presenting outcome
probabilities
2. The decision support technology specifies the defined group (reference class) of patients for which the outcome probabilities
apply.
3. The decision support technology specifies the event rates for the outcome probabilities (in natural frequencies).
4. The decision support technology specifies the time period over which the outcome probabilities apply.
5. The decision support technology allows the user to compare outcome probabilities across options using the same denominator
and time period.
6. The decision support technology provides information about the levels of uncertainty around event or outcome probabilities (e.g.
by giving a range or by using phrases such as ‘‘our best estimate is…’’)
7. The decision support technology provides more than one way of viewing the probabilities (e.g. words, numbers, and diagrams).
8. The decision support technology provides balanced information about event or outcome probabilities to limit framing biases.
Values 1. The decision support technology describes the features of options to help patients imagine what it is like to experience the
physical effects.
Clarifying and expressing
values
2. The decision support technology describes the features of options to help patients imagine what it is like to experience the
psychological effects.
3. The decision support technology describes the features of options to help patients imagine what it is like to experience the social
effects.
4. The decision support technology asks patients to think about which positive and negative features of the options matter most to
them.
Decision Guidance 1. The decision support technology provides a step-by-step way to make a decision.
Structured guidance in
deliberation and
communication
2. The decision support technology includes tools like worksheets or lists of questions to use when discussing options with a
practitioner.
Development 1. The development process included finding out what clients or patients need to prepare them to discuss a specific decision
Using a systematic
development process
2. The development process included finding out what health professionals need to prepare them to discuss a specific decision with
patients
3. The development process included expert review by clients/patients not involved in producing the decision support technology
4. The development process included expert review by health professionals not involved in producing the decision aid.
5. The decision support technology was field tested with patients who were facing the decision.
6. The decision support technology was field tested with practitioners who counsel patients who face the decision.
Evidence 1. The decision support technology (or associated documentation) provides citations to the studies selected.
Using evidence 2. The decision support technology (or associated documentation) describes how research evidence was selected or synthesized.
3. The decision support technology (or associated documentation) provides a production or publication date.
4. The decision support technology (or associated documentation) provides information about the proposed update policy.
5. The decision support technology (or associated documentation) describes the quality of the research evidence used.
Disclosure 1. The decision support technology (or associated technical documentation) provides information about the funding used for
development.
Disclosure and transparency 2. The decision support technology includes author/developer credentials or qualifications.
Plain Language 1. The decision support technology (or associated documentation) reports readability levels (using one or more of the available
scales).
Using plain language
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Discussion
Principal Findings
This work demonstrates that IPDASi has the potential to assess
the quality of DSTs. The four stage process revealed the need to
make significant changes in the IPDAS checklist and modifications
to the set of assumptions so that a measurement tool could be
applied across the range of all possible DSTs. Having undertaken
this work, we also suggest that IPDASi could provide formative
feedback about dimensions in which DST developers could make
improvements to subsequent versions. A short-form may also
support the development of rapidly applicable quality standards.
In addition, the study demonstrated the high correlation between
IPDASi and IPDASi-SF, demonstrating support for the instru-
ment’s ability to provide correspondence between scores that
indicate high quality at detailed dimension assessment and a
version with focus on fewer items.
The study also displayed the levels of measurement imprecision
when two raters assess each tool, and points to the need to ensure
rater calibration and training in the use of IPDASi prior to
assessment. We propose that IPDASi ratings should therefore be
undertaken by raters who are familiar with DST development and
use and who have undergone calibration training.
Strengths and weaknesses
The instrument design is based on prior international consensus
which provided a framework in which to assess DST quality, and
in addition, a set of criterion-based ‘items’ for a new instrument.
Secondly, the work was planned by researchers who followed a
detailed protocol and met regularly. Thirdly, a staged approach
was used, adopting the principles of instrument development [16].
Limitations of the study included the limited size of the sample and
our focus on only DSTs developed in English, a constraint
imposed by resource availability. There are also further opportu-
nities to examine the validity of IPDASi, for example by
examining whether low IPDASi scores for the ‘probability
information’ dimension are associated with low patient knowledge
about probabilities, when measured in controlled trials. Addition-
ally, the raters used in the second and third stages were all
researchers in the DST field and had some content expertise, so it
is likely that raters with more diverse backgrounds may not
perform as well. There was no opportunity in this study to provide
intensive group training to all raters to ensure tight calibration and
standardisation of item interpretation. To mitigate against this
weakness, a detailed online manual that provided details about
scale anchor definitions was available. Nonetheless, the results
indicate that there is room to improve inter-rater reliability.
Results in context
Two other studies have used the IPDAS checklist. Coulter et al
undertook a detailed assessment of 40 information materials to
support people inmakingdecisions about their health andhealth care
[17]. They found that the overall quality of informationwas poor and
no systematic processes were adopted to give attention to
presentational issues, such as readability or to ensure the validity of
evidence. O’Connor et al used the checklist to assess the registered
trials and found that several IPDAS process measures had not been
used [13].Williams used IPDASi v2 to assessDSTs for genetic testing
for breast cancer [18]. We are not aware of any other work that has
developed a quantitative measure of DST quality.
Implications
IPDASi, and IPDASi-SF, will be available as a quality assessment
method to developers, researchers and purchasers, and given a
recognised need to set standards and achieve benchmarks, will be
subject to further development. The existing IPDASi provides an
assessment of the quality of a DST’s components, and in the absence
of anyothermethod,will be used as a tool to provide formative advice
to DSTs developers and as a summative assessment for those who
want to compare their tools against existing benchmarks (http://
www.ipdasi.org). In due course, data from these assessments might
form a platform for potential certification but questions remain.
There is for instance only one dimension on evaluation outcomes.
The items in this dimension cannot be scored unless the developers
have actually conducted an evaluation. It is likely that developers
may assert that not all DSTs require evaluation, provided they meet
other requirements.However,we contend that research in this field is
at an early stage. There is no agreement as yet on the essential ‘active’
components of DSTs [19]; moreover the theoretical underpinning
for both their mode of action, measurement models and implemen-
Dimension Item
DST Evaluation 1. There is evidence that the decision support technology improves the match between the features that matter most to the
informed patient and the option that is chosen
2. There is evidence that the patient decision support technology helps patients improve their knowledge about options’ features
Test (for DSTs that are
directed at investigations or
screening tests)
1. The decision support technology describes what the test is designed to measure.
2. The decision support technology includes information about the chances of having a true positive test result.
3. The decision support technology includes information about the chances of having a true negative test result.
4. The decision support technology includes information about the chances of having a false positive test result.
5. The decision support technology includes information about the chances of having a false negative test result.
6. If the test detects the condition or problem, the decision support technology describes the next steps typically taken.
7. The decision support technology describes the next steps if the condition or problem is not detected.
8. The decision support technology describes the chances that the disease is detected with and without the use of the test.
9. The decision support technology has information about the consequences of detecting the condition or disease that would never
have caused problems if screening had not been done (lead time bias).
doi:10.1371/journal.pone.0004705.t003
Table 3. cont.
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tation strategies needs strengthening [20,21]. Further work is needed
to assesswhichDSTsdesigns are superior to one another. Prospective
studies that compare theoretically derived DSTs components and
deliberation tools are required to help explore these areas.
The IPDAS collaboration and the resulting instruments
(IPDASi and IPDASi-SF) need to meet the following challenges:
How can new dimensions and items be considered? How are valid
‘option menus’ in DSTs derived and agreed when there are
complex debates about equity, economics and evidence? Should
there be items that assess the use of theory in the development of
these methods, given that these are examples of ‘complex
interventions’ and deserve attention to frameworks of design and
mode of action [22]. These challenges provide an agenda for
future research.
What this paper adds
What is already known on this subject. Interest in decision
support technologies is rapidly increasing and they are being
accessed by ever larger number of patients, especially in the
United States.
A quality checklist for decision support technologies has been
published by the International Patient Decision Aid Standards
Collaboration.
The checklist was not designed to provide precise, quantitative
assessments about the quality these interventions.
What this study adds. Describes the development of an
instrument which can assess the quality of decision support
technologies, thereby enabling formative and summative feedback
to developers and purchasers.
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